Desheng's domestic IVD market development trend

Desheng is a high-tech enterprise specializing in the research, development, production and sales of in vitro diagnostic reagents. It has formed its own intellectual property rights and professional production research and development capabilities in blood collection tube additives. Has accumulated rich knowledge and experience in the pretreatment of blood specimens and has professional technical service advantages. Desheng is positioned as a professional manufacturer and service provider of blood test reagents and polymer materials, and provides professional services and high-quality products for domestic and foreign blood collection tubes, diagnostic reagent manufacturers and polymer material companies.

Desheng has been devoted to the field of in vitro diagnostic reagents, and regards it as a world-class excellent biochemical enterprise as its development vision. I hope that through unremitting efforts to find our territory in in vitro diagnostic reagents. We are determined to become an enterprise with core competence and core competitiveness in a subdivided professional field, and an enterprise with a high sense of social responsibility and high cohesion.

Desheng company location map

In Vitro Diagnostic Reagents (IVD) refers to a diagnostic method that takes samples (blood, body fluids, tissues, etc.) from the human body and then detects them to determine disease or body function. It involves molecular biology, genetic diagnostics, and translational medicine.

In recent years, the IVD industry has shown a rapid development. In 2018, the global IVD market size was about 68 billion U.S. dollars, and the domestic IVD market size was about 600.4 billion yuan, an increase of 18.43% year-on-year. It is predicted that it will maintain an annual growth rate of more than 15% in 10 years. China has become the world's fastest growing market for IVD one.

The IVD global market structure is highly concentrated. The five major companies Roche, Abbott, Danaher, Siemens and Thermo Fisher accounted for 57% of the global market in 2017, and the domestic market was also accounted for by more than 56% of the market share of the five major multinational giants. Of the 1,200 IVD companies in China, Mindray Medical, the largest group, accounts for only about 3.1%.

However, from 2012 to 2017, more and more domestic enterprises gradually increased their market share, and future domestic substitution is a great opportunity. At present, most of the domestic low-end technology areas of the IVD industry in China have achieved localization, such as enzyme-linked immunoassay technology and clinical biochemical diagnostic technology, and the molecular diagnostic technology that shined in this epidemic also reflects the innovation of domestic enterprises. Spirit and R&D strength.

With the growth of China's scientific and technological level, the country's strong support for independent innovation, and the increased investment in R&D funds by various enterprises, the domestic IVD field has maintained steady growth. In the future, China's IVD industry will gradually complete import substitution and gradually open up the European and American markets. The development space is worth looking forward to.